Latest Proteomics News

Proteomics-Based Platform for Monoclonal Antibody Preparation May Replace Hybridoma TechniquesA new proteomics-based tool for preparation of highly purified monoclonal antibodies is now available for biotech and other life...

Oryzon Nominates Specific LSD1 Inhibitor as Drug Candidate to Enter Preclinical Development in Acute Leukemia and Other Hematological CancersOryzon announced today that it is entering preclinical development with its second drug candidate, a first-in-class specific Lysine Specific Demethylase 1 (LSD1) inhibitor for the treatment of hematological cancers. LSD1 inhibition reduced tumor load especially in acute leukemia models by targeting Leukemia Stem Cells, while normal myeloid progenitor cells were spared. Barcelona, Spain (PRWEB) May...

AB SCIEX Expands Its iChemistry™ Solutions Portfolio With Sensitivity-enhancing Reagents for Mass SpectrometryAB Sciex Pte. Ltd., a global leader in life science analytical technologies, today announced the commercial availability of Amplifex™ Reagents, the first of a new family of advanced chemistries designed to boost the performance of mass spectrometers, improve data precision and significantly increase sensitivity beyond conventional limits. The new reagen...

AB SCIEX Launches Next-generation TripleTOF™ 5600 SystemAB SCIEX, a global leader in life science analytical technologies, today announced the launch of the second generation of the TripleTOF™ 5600 System. The new TripleTOF™ 5600± System delivers new innovation for biomolecule research with MS/MSALL with SWATH™ Acquisition and supports a higher level of selectivity when coupled with SelexION�

Genedata and Roche Extend Collaboration of Biomarker Discovery for Personalized HealthcareGenedata Expressionist® for Mass Spectrometry license renewal integral to Roche advancement of personalized healthcare; Software will demo at 60th ASMS Conference Vancouver, British Columbia (PRWEB) May 21, 2012 Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Roche renewed the licensing agreement of Genedata Expre...

Bruker Announces the Release of New nano-Advance UHPLC for Proteomics

Sale-zomeEbb & Flow Sale-zome VCs will barely make a return on their investment in German proteomics play Cellzome AG, which is being acquired by long-time partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). GSK last week said…

GSK buys more of TheravanceGlaxoSmithKline now owns more than a quarter of biopharma company Theravance after shelling out nearly $213 million to buy ten million extra shares. GSK has upped its stake significantly from 18.3% to 26.7% of Theravance’s total outstanding c...

NEC, SomaLogic release professional software toolSomaLogic, Inc., and NEC Corporation today announced the release of SomaSuite, a professional software tool developed by NEC that provides simple, reliable and direct access to the highly multiplexed proteomic data generated by SomaLogic's SOMAscan p...

GSK to fully acquire Cellzome for £61 millionGlaxoSmithKline plc has entered into an agreement to acquire those shares it does not currently own in proteomics technologies specialist company Cellzome for £61 million (US$99 million). Cellzome, a privately owned company with laboratories in Camb...

GlaxoSmithKline to fully acquire Cellzome for $97.2 millionGlaxoSmithKline has entered into an agreement with Cellzome, a privately-held chemical proteomics company, to acquire all shares in the company it does not currently own for $99 million in cash. Cellzome, which has laboratories in Cambridge, U.K., an...

GSK buying proteomics company for $99MGlaxoSmithKline agreed to pay $99 million to buy the remaining 80% stake in Cellzome. -More-

GSK Buys Proteomics CompanyFox Business | GlaxoSmithKline has purchased the remaining percentage of Cellzome for about $98 million in cash.

GSK £61m buy-out rescues Cellzome platform from venture wastelandThe £61 million purchase of Cellzome gives GlaxoSmithKline a cutting-edge platform in proteomics. However, the real story behind the acquisition is one of a small company running out of money and venture investors running out of time to g...

GlaxoSmithKline to fully acquire Cellzome for GBP 61 millionGSK to further expand its platform technology expertise with acquisition of chemical proteomics company

GSK to acquire CellzomeGlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will acquire the 80.02% of proteomics company Cellzome AG (Heidelberg, Germany) it does not already own for L61 million ($98 million) in cash. GSK said Cellzome's proteomic mass spectrometry and screening capab...

GlaxoSmithKline to Fully Acquire Cellzome for £61 MillionGlaxoSmithKline to fully acquire Cellzome for £61 million Issued: Tuesday 15 May 2012, London UK GSK to further expand its platform technology expertise with acquisition of chemical proteomics company GlaxoSmithKline plc (GSK) today announced.....

KineMed to Discuss New Applications of Biomarkers for Neurodegenerative Therapeutics at the 7th Annual Neurotech Investing & Partnering ConferenceKineMed Inc. (www.kinemed.com) announced today that David Fineman, KineMed’s President & CEO, will be a panelist in the session titled “Movement Disorders: Parkinson’s, Huntington’s, and ALS” being held at the 7th annual Neurotech Investing & Partnering Conference at 3:30 PM EST May 21st at the Intercontinental Hotel Boston....

GlaxoSmithKline to acquire Cellzome for £61 millionGlaxoSmithKline will expand its platform technology capability with the acquisition of a chemical proteomics company. GSK will acquire those shares it does not currently own in Cellzome for £61 million ($99 million) in cash. GSK currentl...

GlaxoSmithKline to fully acquire Cellzome for £61 millionGlaxoSmithKline plc (GSK) today announced that it has entered into an agreement to acquire those shares it does not currently own in Cellzome, a leader in the development and advancement of proteomics technologies, for £61 million (US$99 million) in...

CHDI, KineMed partner to investigate turnover rates of huntingtin proteinKineMed, Inc. and CHDI Foundation, Inc. announced today a collaboration to use KineMed's isotopic labeling and dynamic proteomics platform to investigate the turnover rates of huntingtin protein, a mutant form of which plays a central role in the pat...

KineMed and CHDI Foundation Collaborate to Develop New Biomarkers of Disease Progression and to Evaluate Potential Therapeutics for Huntington’s DiseaseKineMed, Inc. (www.kinemed.com) and CHDI Foundation, Inc. announced today a collaboration to use KineMed’s isotopic labeling and dynamic proteomics platform to investigate the turnover rates of huntingtin protein, a mutant form of which plays a central role in the pathogenesis of Huntington’s disease (HD). There are currently no therape...

Cell Signaling Technology, Inc. Develops Novel Monoclonal Antibody Discovery PlatformCell Signaling Technology, Inc. (CST) of Danvers, MA is pleased to announce the development of a new discovery platform for antigen-specific monoclonal antibodies. This novel antibody discovery technology, named NG-XMTTM, harnesses the power of proteomics to identify and clone antigen-specific monoclonal antibodies directly from the circulating serum of an...

Researchers describe a new target for developing anti-angiogenic and anti-tumoral therapiesResearchers from the Spanish National Cancer Research Centre (CNIO), led by Jorge L. Martínez-Torrecuadrada from the Proteomics Unit, have demonstrated that the antibody-based blocking of ephrinB2, a protein involved in angiogenesis and lymphoan...

NCKU Student Wins Prestigious Award for Anti-Cancer ResearchWan-Pei Su, a graduate student of Molecular Medicine at National Cheng Kung University (NCKU), southern Taiwan, has received a Graduate/Postdoctoral Travel Award from the American Society for Biochemistry and Molecular Biology (ASBMB) to attend the annual conference on Experimental Biology (EB) in San Diego in April 2012. NCKU President Hwung-Hwen...

0 1 2 3 4 ›»

buy Proteomics market research data and corporate reports now Advertisement